Who we are
PM Life Sciences is rooted in a rare blend of clinical insight, commercial acumen, and political experience - making PM Life Sciences uniquely placed to support clients looking to deliver meaningful impact in healthcare.
Dr Sheuli Porkess
Dr. Sheuli Porkess is a highly respected life sciences consultant and physician, renowned for her expertise in medical affairs, pharmaceutical medicine, and life sciences policy. Sheuli brings deep industry experience to her work with SMEs and start-ups, helping them navigate medical strategy, and commercialisation challenges.
Sheuli has led new business unit development within health technology firms, focusing on product lifecycle management and evidence-based decision-making. As the former Executive Director for Research, Medicine and Innovation at the ABPI, her leadership extends to policy development, including membership and chairing of various advisory boards and shaping initiatives on digital health & AI, multimorbidity, women’s health, antimicrobial resistance, environmental sustainability and patient involvement.
She is known for her ability to bridge industry, academia, and government, offering practical insights that foster innovation and growth. Her collaborative approach and commitment to patient-centric solutions make her a trusted partner for organisations aiming to make a positive impact in the life sciences sector.
A sought-after speaker, Sheuli also serves as President of the Faculty of Pharmaceutical Medicine.
Dr David Montgomery
Dr David Montgomery is a medical doctor and senior life sciences leader with 25 years experience spanning the pharmaceutical industry, the NHS, health charity and the wider health and research ecosystem. He has launched multiple medicines across more than twenty indications and played an influential role in shaping the UK’s reimbursement and market access landscape — including service on national advisory and decision-making committees.
A Fellow of the Faculty of Pharmaceutical Medicine, David has contributed extensively to policy and strategy development across professional, academic, and industry spheres. His career reflects a consistent focus on translating science into impact — building bridges between innovation, healthcare delivery, and policy.
Alongside his corporate leadership, David advises early-stage healthtech and biotech ventures as an angel investor and non-executive director, supporting founders on scientific, strategic, and commercial issues.